Detailed notes: Biomarker-Based Diagnosis and Risk Stratification in Sepsis-Associated Acute Kidney Injury

---

1. Central message

• Cellular stress
• Tubular epithelial injury or dysfunction
• Systemic and renal inflammation
• Endothelial and microcirculatory dysfunction
• Mitochondrial dysfunction and oxidative stress
• Functional loss of filtration
• Variable repair, recovery, or progression to chronic kidney disease (CKD)

---

2. Why conventional AKI diagnosis is insufficient

KDIGO AKI criteria

• Serum creatinine increase of at least 0.3 mg/dL within 48 hours
• Serum creatinine at least 1.5 times baseline within 7 days
• Urine output less than 0.5 mL/kg/h for 6 hours

Limitations in sepsis

• Non-steady-state renal function in critical illness
• Fluid resuscitation causing creatinine dilution
• Low muscle mass and altered creatinine generation
• Delay between cellular injury and decline in glomerular filtration
• Vasopressor use, diuretics, and changing volume status affecting urine output

---

3. Pathophysiology of SA-AKI

Key concept

Main mechanisms

Immune-inflammatory pathway

1. Microbial products, such as lipopolysaccharide, are recognized by TLRs.
2. TLR signaling activates NF-kB and IRF3.
3. This increases inflammatory cytokines and chemokines.
4. Endothelial injury, vascular permeability, leukocyte migration, and microthrombus formation follow.
5. Peritubular capillary blood flow becomes uneven, producing focal renal hypoxia.
6. Tubular cells shift toward stress-adaptive metabolism, including glycolysis.
7. Persistent stress can progress from reversible dysfunction to structural injury and maladaptive repair.

AKI to CKD transition

---

4. Biomarker classification

---

5. Individual biomarkers

A. NGAL: neutrophil gelatinase-associated lipocalin

• Released by injured tubular epithelium and neutrophils.
• Measured in plasma or urine.
• Reflects tubular stress, injury, and inflammation.

• Can rise in approximately 2 to 6 hours after renal injury.
• May increase 24 to 48 hours before conventional creatinine-based AKI detection.

• Early detection of tubular injury
• Risk prediction
• Distinguishing transient from persistent AKI in some settings
• Monitoring nephrotoxic injury, including drug-associated AKI

• Extensive study base
• Rapid early signal
• Both blood and urine testing possible

• Not kidney-specific in sepsis
• May rise because of systemic inflammation, infection, neutrophil activation, CKD, or multiorgan dysfunction
• Cutoffs differ by assay, specimen, timing, and clinical population

• Reported sepsis cohort sensitivity: 75% to 89%
• Reported specificity: 70% to 85%
• In a cited SA-AKI meta-analysis, urinary NGAL had SROC approximately 0.907.

---

B. KIM-1: kidney injury molecule-1

• A transmembrane glycoprotein expressed by proximal tubular cells after injury.
• Most commonly measured in urine.

• Usually rises around 12 to 24 hours after injury.
• Peaks approximately 24 to 48 hours after injury.

• Diagnosis of tubular injury
• Estimation of severity and recovery potential
• Drug-induced AKI, including vancomycin-associated AKI

• Directly linked to proximal tubular injury
• Particularly promising in SA-AKI diagnostic studies

• Baseline elevation can occur with CKD.
• Assay and threshold heterogeneity remain major barriers.

• In a 49-study SA-AKI synthesis involving 4,189 patients, urinary KIM-1 had the highest reported SROC: 0.931.

---

C. [TIMP-2]·[IGFBP7]: renal stress and cell-cycle arrest markers

• TIMP-2 and IGFBP7 reflect G1 cell-cycle arrest in stressed tubular cells.
• Cell-cycle arrest may be protective early in injury because it prevents damaged cells from continuing through division.
• A positive result indicates tubular stress and vulnerability, not necessarily established tubular necrosis.

• The most mature biomarker approach in the article for short-term prediction of moderate-to-severe AKI in critically ill adults.
• Commercially available as the urinary NephroCheck test.

• SAPPHIRE cohort: AUROC approximately 0.80 for predicting KDIGO stage 2-3 AKI within 12 hours.
• TOPAZ cohort: AUROC approximately 0.82.
• At the 0.3 cutoff in TOPAZ: sensitivity 92%, specificity 46%.

• The low cutoff is designed to be sensitive. Therefore, many positive tests may not progress to severe AKI.
• It should prompt a prevention and surveillance bundle, not a diagnosis of AKI in isolation.

• The foundational validation studies were in heterogeneous critically ill populations. Sepsis-specific evidence is less extensive than the overall ICU evidence base.

---

D. Cystatin C

• A cysteine protease inhibitor produced by nucleated cells.
• Less influenced by muscle mass than serum creatinine.
• Used as a functional marker of reduced GFR.

• May increase within 12 to 24 hours after AKI onset.
• Its short half-life supports repeat measurement and dynamic monitoring.

• Earlier functional assessment than creatinine in some critically ill patients.
• Can complement a structural injury marker such as NGAL or KIM-1.

• Age, sex, body composition, hypoalbuminemia, systemic inflammation, and high-dose corticosteroids may influence serum cystatin C.
• Severe sepsis itself can elevate cystatin C independently of renal function.

---

E. penKid: proenkephalin A 119-159

• A plasma biomarker associated with glomerular filtration.
• Proposed as a functional marker, potentially useful when creatinine kinetics are unreliable.

• Identifying subclinical AKI
• Predicting mortality, AKI progression, need for vasopressor support, and renal recovery in selected studies

• penKid ≥80 pmol/L at 12-24 hours, in a patient without conventional AKI criteria, may identify higher risk.

• The article treats this threshold as protocol-dependent and not ready to function as a universal independent decision rule.
• Evidence for using penKid to guide stopping renal replacement therapy is exploratory.

---

F. CCL14: urinary C-C motif chemokine ligand 14

• Reflects renal inflammation.
• More useful for persistent or progressive severe AKI than for the earliest diagnosis.

• Prognosis once moderate-to-severe AKI is already established.
• Predicts persistence of severe AKI and failure of renal recovery.

• In the RUBY cohort, urinary CCL14 predicted persistent or progressive severe AKI at 72 hours with AUROC approximately 0.83.

• CCL14 is a trajectory biomarker, not a first-line screening marker before AKI develops.
• It can help plan monitoring intensity, fluid targets, and possible future need for renal replacement therapy.

---

G. IL-18

• A pro-inflammatory cytokine detected in urine after proximal tubular injury.
• Associated with inflammatory renal damage.

• Possible early prediction and diagnosis of AKI.
• More informative in combination with other tubular injury markers.

• Poor organ specificity in systemic inflammatory states.
• Should not be interpreted alone in sepsis.

• Urinary IL-18 had an SA-AKI SROC of approximately 0.861 in the cited meta-analysis.

---

H. L-FABP and NAG

• Cytoplasmic protein in proximal tubular cells.
• Increases in hypoxia, ischemia, and oxidative stress.
• May be useful in critically ill, perioperative, and contrast-associated AKI settings.

• Lysosomal enzyme released in proximal tubular injury.
• May rise before conventional filtration markers.
• Reflects lysosomal injury, oxidative stress, mitochondrial disruption, and regulated cell death.

---

I. suPAR and urinary sTREM-1

• Represents systemic immune activation and inflammatory burden.
• Potentially identifies patients with greater risk of disease progression and multiorgan injury.

• Reflects neutrophil and myeloid activation.
• Conceptually relevant in infection-associated AKI.

---

J. MicroRNAs and omics biomarkers

• miR-21
• miR-155
• miR-210

• Poor replication across cohorts
• Variable pre-analytic handling
• Different normalization methods
• Unstandardized thresholds
• Limited external validation

---

6. Why multimarker panels are preferred

Rationale

Proposed minimum practical panel

1. Stress: urinary [TIMP-2]·[IGFBP7]
2. Tubular injury: NGAL, with KIM-1 as an alternative or complement
3. Function: cystatin C, with penKid as a potential alternative

---

7. Timing of biomarker measurement

Sampling windows proposed by the article

Main principle

• Baseline kidney function
• Urine output
• Serum creatinine trend
• Timing of sepsis onset and resuscitation
• Hemodynamic state
• Fluid balance and venous congestion
• Nephrotoxic exposure
• Inflammatory burden
• Assay method and local validated thresholds

---

8. Suggested clinical interpretation algorithm

Step 1: At sepsis recognition or ICU admission

• Assess risk factors: CKD, diabetes, older age, shock, vasopressor need, exposure to nephrotoxins, contrast, fluid overload, and prior AKI.
• Use KDIGO criteria and baseline clinical assessment.
• Consider urinary [TIMP-2]·[IGFBP7] where available.

Step 2: If [TIMP-2]·[IGFBP7] is at least 0.3

• Intensify urine output and creatinine surveillance
• Review nephrotoxins and dose-adjust medicines
• Optimize renal perfusion and hemodynamics
• Avoid excessive fluid accumulation and venous congestion
• Review need for contrast exposure
• Repeat renal assessment after initial resuscitation

Step 3: At 6-24 hours

• Add NGAL or KIM-1 to identify tubular injury.
• Add cystatin C or penKid to assess functional impairment before creatinine reaches a steady state.
• Interpret a positive injury marker in relation to systemic inflammatory activity and assay characteristics.

Step 4: At 48-72 hours in established moderate-severe AKI

• Consider CCL14 for likelihood of persistence or progression.
• Use this to guide monitoring, fluid targets, communication, and anticipatory planning.
• Do not use CCL14 alone to start renal replacement therapy.

Step 5: Continue KDIGO-based monitoring

• Creatinine
• Urine output
• Acid-base status
• Potassium
• Fluid status
• Pulmonary edema or oxygenation
• Uremic complications
• Overall clinical trajectory

---

9. Treatment principles in SA-AKI

Core supportive management

• Prompt sepsis source control
• Appropriate antimicrobials
• Hemodynamic stabilization
• Individualized fluid therapy
• Avoid sustained hypotension
• Avoid unnecessary nephrotoxins
• Therapeutic drug monitoring for nephrotoxic agents such as vancomycin
• Avoid persistent hyperglycemia
• Consider alternatives to iodinated contrast where possible
• Assess congestion, not just arterial pressure or fluid responsiveness

Fluid strategy

• Type
• Dose
• Duration
• De-escalation plan

Renal replacement therapy

• Refractory hyperkalemia
• Severe metabolic acidosis
• Refractory pulmonary edema or fluid overload
• Uremic complications
• Persistent clinically significant metabolic derangements

---

10. Evidence appraisal and limitations

Major strengths of the review

• Integrates molecular mechanisms, biomarker kinetics, diagnostic performance, and clinical application.
• Clearly separates biomarker categories by biological function.
• Emphasizes context, serial monitoring, and phenotype-based interpretation.
• Avoids claiming that one marker is universally superior.
• Discusses maturity of evidence and distinguishes validated from exploratory biomarkers.

Important limitations of the underlying evidence

1. Narrative review design
   It is a structured narrative review, not a systematic review with pooled quantitative analysis.
2. Study heterogeneity
   Differences in:
   • Sepsis definitions
   • AKI reference definitions
   • Sample type: plasma versus urine
   • Timing of collection
   • Assay platform
   • Biomarker cutoffs
   • Baseline CKD prevalence and illness severity
3. Imperfect reference standard
   Creatinine is a delayed and confounded comparator in critical illness. This makes validation of an “early” biomarker difficult.
4. Inflammatory confounding
   NGAL, KIM-1, IL-18, cystatin C, and other markers can rise in systemic inflammation, CKD, infection, or multiorgan dysfunction even without definite intrinsic kidney injury.
5. Limited sepsis-specific validation
   Much evidence is from general ICU, postoperative, or mixed-AKI populations and is extrapolated to SA-AKI.
6. Clinical utility remains uncertain
   Better prediction does not automatically mean better patient outcomes. Biomarker-guided pathways must demonstrate that they change management and improve meaningful outcomes.

---

11. Future directions proposed

• Standardized sampling windows and thresholds
• Assay harmonization across platforms
• External validation in well-defined SA-AKI cohorts
• Multimarker panels spanning stress, injury, function, inflammation, and recovery
• Single-cell transcriptomics, proteomics, metabolomics, and epigenomics
• Biomarker-guided clinical trials
• Mechanism-based therapeutic trials targeting:
  • Mitochondrial dysfunction
  • Endothelial and glycocalyx injury
  • Microvascular dysfunction
  • Innate immune activation
  • Ferroptosis and regulated necrosis pathways
  • Maladaptive repair
• AI-based risk models, only after validation for calibration, transportability, transparency, and clinical impact

---

12. Exam-oriented high-yield summary

• SA-AKI is a heterogeneous syndrome driven by inflammation, microcirculatory dysfunction, endothelial injury, tubular stress, mitochondrial dysfunction, and maladaptive repair.
• Creatinine and urine output diagnose functional AKI late; they remain mandatory but incomplete.
• [TIMP-2]·[IGFBP7] is primarily an early renal-stress and short-term risk marker.
• NGAL, KIM-1, and IL-18 reflect tubular injury, but are confounded by inflammation and systemic illness.
• Cystatin C and penKid reflect renal functional change and may be useful when creatinine is unreliable.
• CCL14 predicts persistence and progression after moderate-to-severe AKI has developed.
• The most sensible approach is multimarker, phenotype-aware, and serial, combined with KDIGO criteria and clinical assessment.
• A biomarker elevation should trigger prevention, reassessment, and closer monitoring, not automatic diagnosis of intrinsic AKI or automatic RRT.
• miRNAs and omics panels are promising research tools but are not ready for routine bedside use.